Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,357 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Terminated Phase 2 Interventional

Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal

NCT00333060
View directory record Official record
Conditions
Epiretinal Membrane, Macular Hole
Interventions
OT-551 ophthalmic solution
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
Peoria, Arizona • Beverly Hills, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Not applicable Interventional

Evaluation of a Mobile Digital Solution for Cancer Care and Research

NCT03094741
View directory record Official record
Conditions
Cancer, Caregivers, Quality of Life
Interventions
CancerLife
Other
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers

NCT01205373
View directory record Official record
Conditions
Healthy
Interventions
BI 671800
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 28, 2026, 1:21 PM EDT
Not yet recruiting Phase 4 Interventional

Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain

NCT07849803
View directory record Official record
Conditions
Ocular Pain, Dry Eye
Interventions
acoltremon ophthalmic solution 0.003%
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00909779
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
73
States / cities
Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes

NCT06353256
View directory record Official record
Conditions
Preeclampsia Postpartum, Adverse Pregnancy Outcomes
Interventions
usual postpartum care, usual postpartum care + community health worker intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 56 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Not applicable Interventional

ULTRAPREP Used to Perform Skin Antisepsis Outside the Operating Room

NCT04600310
View directory record Official record
Conditions
Time Saved Performing Skin Antisepsis Process Outside the OR, Antisepsis of Skin Preparation Outside the OR
Interventions
ULTRAPREP, No Intervention
Device
Lead sponsor
Prep Tech, LLC
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Westlake, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

NCT02040623
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution
Drug · Other
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Plantation, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

NCT05910450
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
North Little Rock, Arkansas • San Diego, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

NCT00755183
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 28, 2026, 1:21 PM EDT
Withdrawn Not applicable Interventional

Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma

NCT01489410
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Drug-Eluting Beads (DEB) with Doxorubicin, Lipiodol Ethanol Mixture
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Safety Study of A-101 Solution

NCT02667288
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 28, 2026, 1:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease

NCT04510896
View directory record Official record
Conditions
Hereditary Cancer-Predisposing Syndrome
Interventions
InheRET, Patient Acceptance, Physician Acceptance Survey
Other
Lead sponsor
InheRET, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Ann Arbor, Michigan • Flint, Michigan • Saginaw, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 28, 2026, 1:21 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

NCT03307512
View directory record Official record
Conditions
Safety and Tolerability
Interventions
inhaled human insulin, Insulin Lispro (Humalog U-100)
Drug
Lead sponsor
Dance Biopharm Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 28, 2026, 1:21 PM EDT
Recruiting No phase listed Observational

Extracorporeal Photopheresis in Sezary Syndrome

NCT05157581
View directory record Official record
Conditions
Sezary Syndrome
Interventions
Extracorporeal photopheresis (ECP), Methoxsalen Injection
Device · Drug
Lead sponsor
Oleg E. Akilov, MD, PhD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses

NCT01053000
View directory record Official record
Conditions
ACTINIC KERATOSES
Interventions
Tazorac
Drug
Lead sponsor
Stewart, Roger H., M.D., P.A.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

NCT02194400
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
RSLV-132
Biological
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Clearwater, Florida • Grand Rapids, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

NCT04405245
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Latanoprost ophthalmic solution, AKB-9778 4%, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
21
States / cities
Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

NCT03278028
View directory record Official record
Conditions
Common Wart
Interventions
A-101 Topical Solution, A-101 Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects

NCT03660475
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Naltrexone, Placebos
Drug
Lead sponsor
Sassani, Joseph S., MD, MHA
Individual
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study: Manometry With & Without Lidocaine

NCT03349112
View directory record Official record
Conditions
Normal
Interventions
4% Lidocaine Spray, 2% Viscous Lidocaine
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 4 Interventional Results available

Rocklatan® Evaluation

NCT05283395
View directory record Official record
Conditions
Glaucoma
Interventions
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Mission Hills, California • Newport Beach, California • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 28, 2026, 1:21 PM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

NCT00894530
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Artesia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 28, 2026, 1:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Gait Assessment

NCT05724901
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 28, 2026, 1:21 PM EDT